LY3372993

DRUG3 trials

Sponsors

Eli Lilly and Company

Conditions

Alzheimer DiseaseHealthy

Phase 1

A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)

CompletedNCT03720548

Eli Lilly and CompanyAlzheimer Disease

Start: 2018-11-05End: 2019-05-14Updated: 2019-06-05

A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants

CompletedNCT04451408

Eli Lilly and CompanyAlzheimer Disease, Healthy

Start: 2020-07-07End: 2024-11-18Updated: 2025-03-28

A Study of Remternetug (LY3372993) in Healthy Chinese Participants

Active, not recruitingNCT07346495

Eli Lilly and CompanyHealthy

Start: 2026-01-31End: 2026-08-01Target: 24Updated: 2026-06-17